

Circulating nucleic acids as diagnostic tool

Maurizio Ferrari^{1,2,3}, Laura Cremonesi^{2,3}, Silvia Galbiati^{2,3}

¹Università Vita-Salute San Raffaele, Milano

²Genomic Unit for the Diagnosis of Human Pathologies, Istituto Scientifico San Raffaele, Milano

³Diagnostica e Ricerca S. Raffaele SpA, Milano

ABSTRACT

Circulating nucleic acids are present in small amounts in the plasma of healthy individuals. However, the occurrence of circulating nucleic acids has long been explored for the non-invasive diagnosis of a variety of clinical conditions. Studies focused on various forms of cancer first detected the presence of circulating DNA. Metastasis and recurrence in certain tumours have been associated with the presence of high levels of cancer-derived DNA in circulation. The detection of fetal DNA in maternal plasma is useful in detecting and monitoring fetal diseases and pregnancy-associated complications. Similarly, levels of circulating DNA in acute medical emergencies, including trauma and strokes, have been reported to be increased and explored as indicators of clinical severity. In the last few years, much attention and efforts have been focused on the study of circulating RNA, starting from the detection of tumor-derived RNA in the plasma of cancer patients. Detection of circulating fetal RNA in maternal plasma was also described. Its detection looks to be a promising approach for the development of gender- and polymorphism-independent fetal markers for prenatal diagnosis and monitoring complications during pregnancy. This development also opens up the possibility of non-invasive prenatal gene expression profiling by maternal blood analysis.

NON-INVASIVE PRENATAL DIAGNOSIS

The discovery of cell-free fetal DNA in maternal plasma by Dennis Lo in 1997 outlined new scenarios for non-invasive prenatal diagnosis (1). The quantitative analysis of the free fetal DNA showed that this can represent as much as 6.2% of the total DNA present in the maternal plasma (1). Later, a deep and extensive search for non-invasive techniques of fetal DNA sampling has been carried out to substitute invasive prenatal diagnosis that carry a significant risk of miscarriage.

Fetal DNA release into maternal plasma has been shown to be an early physiological phenomenon, increasing progressively throughout pregnancy (2,3). Circulating fetal DNA molecules (SRY gene) have been detected in maternal plasma in the first trimester (starting from the 5th gestational week) (2,3). This approach has been used for the prenatal investigation of sex-linked diseases and fetal RhD status condition in which the fetus presented a gene absent in the mother.

The majority of research groups use sequences of chromosome Y in male embryos as a marker of fetal DNA and for standardization of the assays, due to the fact that a woman (46,XX) does not possess this chromosome in her genome. Sexing analysis is also important, mainly for diseases with a recessive X-linked pattern of inheritance, with females being normal or carriers of the mutation, but not affected by the disease, while males are normal or affected by the disease. An application of fetal sexing analysis is congenital adrenal hyperplasia (CAH), an autosomal recessive genetic disease, which

carries a defect in 21-hydroxylase deficiency. Homozygous girls for this pathology born with masculinization of the external genitalia and often require surgical operations as opposed to affected boys who present normal external genitalia. Prenatal treatment of CAH with dexamethasone to prevent genital ambiguity has been successfully used (4). However, to minimize the side effects, the interruption of therapy has been recommended in the case of affected or normal male embryos and normal female embryos. For this reason, fetal sexing is necessary during pregnancy and is usually carried out by invasive methods. Noninvasive fetal sexing based on free fetal DNA in maternal plasma would bring the additional advantage of early discontinuation of medication in the case of male embryos (5).

Many genetic diseases are caused by mutations that result in subtle differences between the sequences of maternal and fetal DNA, such as achondroplasia (6) and β -thalassemia (7-9).

Rh alloimmunization is a crucial problem in medical and obstetrical practice, potentially leading to hemolytic disease in the newborn. For pregnant negative Rh women (15% of the population), a positive Rh embryo involves a 16% risk of sensitization to the Rh antigen. Diagnostic procedures and invasive therapy may be necessary to reduce perinatal mortality of positive Rh embryos (10). Hence, the early detection of fetal RhD status through fetal DNA in the plasma of negative Rh mothers is of great importance in defining the need for intervention, with risk of gestational loss, or of gestational immunoprophylaxis.

PREECLAMPSIA AND INTRAUTERINE GROWTH RESTRICTION

Preeclampsia is a hypertensive disorder affecting approximately 5% of pregnancies and is still one of the main causes of mortality of both the fetus and the mother. Typical symptoms are maternal hypertension and proteinuria, which usually develop in the late second or third trimester of pregnancy (11). Increased fetal DNA release can be a marker of pathological conditions affecting both the fetus and the placenta (12-19). Abnormal placentation has often been found to be involved in the pathogenesis of intrauterine growth restriction (IUGR) and preeclampsia, which can occur either isolated or in combination. IUGR is defined as the presence of an ultrasonographically estimated fetal weight below the fifth percentile, confirmed post-natally, in the absence of chromosomal and structural abnormalities. Preeclampsia and IUGR have been linked to abnormalities in trophoblast invasion into the placental bed. During normal pregnancy, trophoblastic invasion of uterine spiral arteries takes place reducing the vascular resistance and allowing adequate fetoplacental blood supply. In IUGR and preeclampsia this adaptive phenomenon is often insufficient, resulting in a diminished infiltration and modification of the spiral arteries, which lead to the maintenance of a high-resistance uterine circulation (20,21). Several studies have addressed the issue of quantifying fetal DNA in maternal plasma in pregnancies complicated by preeclampsia, with a fivefold increased fetal DNA levels in the presence of this pathology (19,22). Since IUGR is mostly caused by impaired placental perfusion, similar to what found in preeclampsia, it might also be associated with high levels of fetal DNA in maternal circulation.

The rate of increase of circulating fetal and maternal DNA would correspond to the degree of severity of the illness and, therefore, the level of fetal DNA could serve as a marker for the prognosis and severity of the clinical picture (23,24).

Although most researchers use the chromosome Y for this specific application, other non-gender markers have been studied, including epigenetic markers, to improve the number of pregnant women who could undergo quantitative investigation (25).

Recently, fetal RNA has also been found in maternal plasma. Such fetal RNA has been shown to originate from the placenta and to be remarkably stable. The use of microarray-based approaches has permitted to rapidly generate new circulating RNA markers. It is hoped that further developments in this field will make easier the practice of non-invasive nucleic acid-based prenatal diagnosis for common pregnancy-associated disorders in the near future.

CANCER

Cancer is a common disease in industrialised countries. Early diagnosis of tumours and accurate identification of haematogenic metastases can improve the suc-

cess of treatment (26-29). Therefore, the detection of single tumour cell released in the blood in early stages could help physicians in choosing the most advantageous therapy for patients. The presence of small amounts of cell-free tumor DNA (cfDNA) circulating in the plasma of cancer patients, first demonstrated 30 years ago, provides a possibility of examining tumour-derived genetic material in the circulation and to detect haematogenic spread of tumour cell DNA (30). Qualitative alterations in circulating DNA, such as microsatellite alterations (31), oncogene mutations (32), mitochondrial DNA, tumour-specific methylated DNA (33) and viral DNA (34), have been found in patients with different types of cancer. Quantitative alterations of circulating cfDNA have also been observed in several tumours, such as prostate cancer (35), lung cancer (36), pancreatic cancer (37), leukaemia and lymphoma (38). High levels of circulating cfDNA were correlated with tumour metastasis, response to therapy and recurrence (36-39). Therefore, tumour-derived circulating nucleic acids in the plasma or serum of cancer patients were introduced as a tool for detection and surveillance of cancers (40).

The proportion of patients with altered cfDNA varies with the pathology and the nature of the marker. However, several studies have reported the presence of altered cfDNA in >50% of cancer patients (41), suggesting that this marker may be common and amenable for a variety of clinical and epidemiological studies. Because the mechanisms and timing of cfDNA released in the blood stream are poorly understood, only few studies have addressed the use of cfDNA for early cancer detection or as a biomarker for mutagenesis and tumorigenesis in molecular epidemiology (41). In some circumstances, cfDNA alterations are detectable prior to cancer diagnosis, raising the possibility of using these biomarkers for detecting cancer occurrence.

TRAUMA

The mechanisms by which cell-free DNA is released into the circulation of human subjects are unknown; one possibility is that DNA is released following cell death (42,43). Direct damage or hemodynamic compromise of the organs responsible for circulating DNA clearance may also lead to increased plasma DNA. Candidate systems include liver, spleen, and kidneys, which may have a role in both liberating and clearing circulating DNA.

In agreement with this hypothesis, Lo et al. suggested that DNA may be liberated from body tissues into the plasma after trauma and that plasma DNA may be a potentially useful prognostic tool (44). In the study, circulating plasma DNA in the peripheral blood of trauma patients increased soon after injury, being related to the development of posttraumatic complications, suggesting that plasma DNA may be a potentially useful marker for monitoring patients after trauma.

STROKE

Stroke ranked as the second leading cause of all

deaths worldwide in 1990, accounting for 4.4 million victims (45), and is also currently the leading cause of brain injury in adults (46). Preventive strategies have led to a decrease in the rate of stroke attacks and deaths. Increased concentrations of several neurobiochemical protein markers have been detected in the peripheral blood of patients with stroke, but at present there is no simple and accurate blood test that may be used to determine the severity of a stroke or to predict mortality and morbidity in stroke patients on arrival in emergency wards in clinical practice.

In a study, plasma DNA concentrations correlated with stroke severity and could be used to predict mortality and morbidity in the emergency room (47). As both hemorrhagic and ischemic strokes involve cell death and disruption of the blood-brain barrier (48), the authors hypothesized that DNA would be liberated into the plasma early after the onset of the stroke and that it might be useful for assessing disease severity and predicting mortality. They also showed that plasma DNA measurements could be useful for early risk stratification and for predicting in-hospital and 6-month disability and mortality. The greatest differences in plasma DNA concentrations between patients with good and poor outcomes occurred within 3 h of the onset of symptoms.

The mechanisms by which circulating cell-free DNA increases after strokes require further study but are likely to be a result of increased liberation from damaged cells. Strokes involve indeed a complicated cascade of events involving cerebral ischemia, altered cerebral blood flow, inflammation, production of reactive oxygen radicals, neuronal necrosis and apoptosis, and neurologic dysfunctions (49-53).

ACKNOWLEDGEMENTS

Funding from the European Commission for the Special Non-Invasive Advances in Fetal and Neonatal Evaluation (SAFE) Network of Excellence (LSHB-CT-2004-503243), Telethon (Project number GG904016) are gratefully acknowledged.

REFERENCES

- Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. *Am J Hum Genet* 1998;62:768-75.
- Birch L, English CA, O'Donoghue K, et al. Accurate and robust quantification of circulating fetal and total DNA in maternal plasma from 5 to 41 weeks of gestation. *Clin Chem* 2005;51:312-20.
- Galbiati S, Smid M, Gambini D, et al. Fetal DNA detection in maternal plasma throughout gestation. *Hum Genet* 2005;117:243-8.
- New MI. An update of congenital adrenal hyperplasia. *Ann N Y Acad Sci* 2004;1038:14-43.
- Rijnders RJ, van der Schoot CE, Bossers B, et al. Fetal sex determination from maternal plasma in pregnancies at risk for congenital adrenal hyperplasia. *Obstet Gynecol* 2001;98:374-8.
- Saito H, Sekizawa A, Morimoto T, et al. Prenatal DNA diagnosis of a single gene disorder from maternal plasma. *Lancet* 2000;356:1170.
- Chiu RW, Lau TK, Leung TN, et al. Prenatal exclusion of α -thalassaemia major by examination of maternal plasma. *Lancet* 2002;360:998-1000.
- Ding C, Chiu RW, Lau TK, et al. MS analysis of single-nucleotide differences in circulating nucleic acids: Application to noninvasive prenatal diagnosis. *Proc Natl Acad Sci USA* 2004;101:10762-7.
- Li Y, Di Naro E, Vitucci A, et al. Detection of paternally inherited fetal point mutations for beta-thalassemia using size-fractionated cell-free DNA in maternal plasma. *JAMA* 2005;293:843-9.
- Lo YM. Fetal RhD genotyping from maternal plasma. *Ann Med* 1999;31:308-12.
- Younis JS, Samueloff A. Gestational vascular complications. *Best Pract Res Clin Haematol* 2003;16:135-51.
- Leung TN, Zhang J, Lau TK, et al. Maternal plasma fetal DNA as a marker for preterm labour. *Lancet* 1998;352:1904-05.
- Lo YM, Lau TK, Zhang J, et al. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. *Clin Chem* 1999;45:1747-51.
- Lo YM, Leung TN, Tein MS, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. *Clin Chem* 1999;45:184-8.
- Sekizawa A, Sugito Y, Iwasaki M, et al. Cell-free fetal DNA is increased in plasma of women with hyperemesis gravidarum. *Clin Chem* 2001;47:2164-5.
- Smid M, Vassallo A, Lagona F, et al. Quantitative analysis of fetal DNA in maternal plasma in pathological conditions associated with placental abnormalities. *Ann N Y Acad Sci* 2001;945:132-7.
- Zhong XY, Laivuori H, Livingston JC, et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. *Am J Obstet Gynecol* 2001;184:414-9.
- Sekizawa A, Jimbo M, Saito H, et al. Increased cell-free fetal DNA in plasma of two women with invasive placenta. *Clin Chem* 2002;48:353-4.
- Smid M, Galbiati S, Lojaco A, et al. Correlation of fetal DNA levels in maternal plasma with doppler status in pathological pregnancies. *Prenat Diagn* 2006;26:785-90.
- Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. *Obstet Gynecol Annu* 1972;1:177-91.
- Lyll F. The human placental bed revisited. *Placenta* 2002;23:555-62.
- Sekizawa A, Farina A, Sugito Y. Proteinuria and hypertension are independent factors affecting fetal DNA values: a retrospective analysis of affected and unaffected patients. *Clin Chem* 2004;50:221-4.
- Zhong XY, Holzgreve W, Hahn S. Circulatory fetal and maternal DNA in pregnancies at risk and those affected by preeclampsia. *Ann N Y Acad Sci* 2001;945:138-40.
- Bischoff FZ, Lewis DE, Simpson JL. Cell-free fetal DNA in maternal blood: kinetics, source and structure. *Hum Reprod Update* 2005;11:59-67.
- Poon LL, Leung TN, Lau TK, et al. Differential DNA methylation between fetus and mother as a strategy for detecting fetal DNA in maternal plasma. *Clin Chem* 2002;48:35-41.
- Pantel K, Muller V, Auer M, et al. Detection and clinical implications of early systemic tumour cell dissemination in breast cancer. *Clin Cancer Res* 2003;9:6326-34.
- Diel IJ, Solomayer EF, Bastert G. Bisphosphonates and the prevention of metastasis: First evidences from precli-

- nical and clinical studies. *Cancer* 2000;88:3080–8.
28. Diel IJ. Antitumour effects of bisphosphonates: First evidence and possible mechanisms. *Drugs* 2000;59:391–9.
 29. Diel IJ, Mundy GR. Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. *International Bone and Cancer Study Group (IBCG). Br J Cancer* 2000;82:1381–6.
 30. Anker P, Stroun M. Circulating DNA in plasma or serum. *Medicina (B Aires)* 2000;60:699–702.
 31. Nawroz-Danish H, Eisenberger CF, Yoo GH, et al. Microsatellite analysis of serum DNA in patients with head and neck cancer. *Int J Cancer* 2004;111:96–100.
 32. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumours. *Proc Natl Acad Sci USA* 2005;102:16368–73.
 33. Wong TS, Kwong DL, Sham JS, et al. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. *Clin Cancer Res* 2004;10:2401–6.
 34. Leung SF, Chan AT, Zee B, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. *Cancer* 2003;98:288–91.
 35. Boddy JL, Gal S, Malone PR, et al. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. *Clin Cancer Res* 2005;11:1394–9.
 36. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. *J Clin Oncol* 2004;22:4157–64.
 37. Giacona MB, Ruben GC, Iczkowski KA, et al. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. *Pancreas* 1998;17:89–97.
 38. Wu TL, Zhang D, Chia JH, et al. Cellfree DNA: measurement in various carcinomas and establishment of normal reference range. *Clin Chim Acta* 2002;321:77–87.
 39. Thijssen MA, Swinkels DW, Ruers TJ, et al. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. *Anticancer Res* 2002;22:421–5.
 40. Goebel G, Zitt M, Zitt M, et al. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. *Dis Markers* 2005;21:105–20.
 41. Gormally E, Caboux E, Vineis P, et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. *Mutation Research* 2007;635:105–17.
 42. Fournie GJ, Martres F, Pourrat JP, et al. Plasma DNA as cell death marker in elderly patients. *Gerontology* 1993;39:215–21.
 43. Fournie GJ, Courtin JP, Laval F, et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. *Cancer Lett* 1995;91:221–7.
 44. Lo YM, Rainer TH, Chan LY, et al. Plasma DNA as a prognostic marker in trauma patients. *Clin Chem* 2000;46:319–23.
 45. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *Lancet* 1997;349:1498–505.
 46. Broderick JP, Brott T, Tomsick T, et al. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. *N Engl J Med* 1992;326:733–6.
 47. Rainer TH, Wong LK, Lam W, et al. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. *Clin Chem* 2003;49:562–9.
 48. Williams GR, Jiang JG, Matchar DB, et al. Incidence and occurrence of total (first-ever and recurrent) stroke. *Stroke* 1999;30:2523–8.
 49. Yang GY, Pang L, Ge HL, et al. Attenuation of ischemia-induced mouse brain injury by SAG, a redoxinducible antioxidant protein. *J Cereb Blood Flow Metab* 2001;21:722–33.
 50. Sairanen T, Carpen O, Karjalainen-Lindsberg M, et al. Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke. *Stroke* 2001;32:1750–8.
 51. Graham SH, Chen J. Programmed cell death in cerebral ischemia. *J Cereb Blood Flow Metab* 2001;21:99–109.
 52. Reed JC. Mechanisms of apoptosis. *Am J Pathol* 2000;157:1415–30.
 53. MacManus JP, Buchan AM. Apoptosis after experimental stroke: fact or fashion? *J Neurotrauma* 2000;17:899–914.